Thus it is likely that tryptophan metabolites, or the administration of IFNα and an IDO1 inhibitor, are in the short term causing their observed effects upon tumor growth by indirect actions upon immune cells, such as altered functionality of intratumoral leukocytes. Here, IDO1 is linked to neoplasm.